Literature DB >> 29222278

Safety profiles of novel agent therapies in CLL.

Inhye E Ahn1, Matthew S Davids2.   

Abstract

A 70-year-old man with relapsed/refractory chronic lymphocytic leukemia has multiple comorbidities including atrial fibrillation (on warfarin for anticoagulation), irritable bowel syndrome, and chronic renal insufficiency. Two years ago, he received bendamustine and rituximab as first-line therapy for chronic lymphocytic leukemia and achieved partial response, but now has relapsed. Fluorescence in situ hybridization cytogenetics reveals deletion 17p. Which novel agent would you recommend for this patient?
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29222278      PMCID： PMC6142609          DOI： 10.1182/asheducation-2017.1.354

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  21 in total

1.  Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

Authors:  Susan O'Brien; Jeffrey A Jones; Steven E Coutre; Anthony R Mato; Peter Hillmen; Constantine Tam; Anders Österborg; Tanya Siddiqi; Michael J Thirman; Richard R Furman; Osman Ilhan; Michael J Keating; Timothy G Call; Jennifer R Brown; Michelle Stevens-Brogan; Yunfeng Li; Fong Clow; Danelle F James; Alvina D Chu; Michael Hallek; Stephan Stilgenbauer
Journal:  Lancet Oncol       Date:  2016-09-13       Impact factor: 41.316

2.  A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.

Authors:  Susan M O'Brien; Nicole Lamanna; Thomas J Kipps; Ian Flinn; Andrew D Zelenetz; Jan A Burger; Michael Keating; Siddhartha Mitra; Leanne Holes; Albert S Yu; David M Johnson; Langdon L Miller; Yeonhee Kim; Roger D Dansey; Ronald L Dubowy; Steven E Coutre
Journal:  Blood       Date:  2015-10-15       Impact factor: 22.113

Review 3.  The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.

Authors:  Darryl P Leong; François Caron; Christopher Hillis; Annie Duan; Jeff S Healey; Graeme Fraser; Deborah Siegal
Journal:  Blood       Date:  2016-05-31       Impact factor: 22.113

4.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

5.  Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Authors:  Stephan Stilgenbauer; Barbara Eichhorst; Johannes Schetelig; Steven Coutre; John F Seymour; Talha Munir; Soham D Puvvada; Clemens-Martin Wendtner; Andrew W Roberts; Wojciech Jurczak; Stephen P Mulligan; Sebastian Böttcher; Mehrdad Mobasher; Ming Zhu; Monali Desai; Brenda Chyla; Maria Verdugo; Sari Heitner Enschede; Elisa Cerri; Rod Humerickhouse; Gary Gordon; Michael Hallek; William G Wierda
Journal:  Lancet Oncol       Date:  2016-05-10       Impact factor: 41.316

6.  Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

Authors:  Paul M Barr; Jennifer R Brown; Peter Hillmen; Susan O'Brien; Jacqueline C Barrientos; Nishitha M Reddy; Steven Coutre; Stephen P Mulligan; Ulrich Jaeger; Richard R Furman; Florence Cymbalista; Marco Montillo; Claire Dearden; Tadeusz Robak; Carol Moreno; John M Pagel; Jan A Burger; Samuel Suzuki; Juthamas Sukbuntherng; George Cole; Danelle F James; John C Byrd
Journal:  Blood       Date:  2017-04-03       Impact factor: 22.113

7.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

8.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Authors:  Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

9.  Idelalisib-associated Colitis: Histologic Findings in 14 Patients.

Authors:  Anna-Sophie Weidner; Nicole C Panarelli; Julia T Geyer; Erica B Bhavsar; Richard R Furman; John P Leonard; Jose Jessurun; Rhonda K Yantiss
Journal:  Am J Surg Pathol       Date:  2015-12       Impact factor: 6.394

10.  Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Andrew D Zelenetz; Jacqueline C Barrientos; Jennifer R Brown; Bertrand Coiffier; Julio Delgado; Miklós Egyed; Paolo Ghia; Árpád Illés; Wojciech Jurczak; Paula Marlton; Marco Montillo; Franck Morschhauser; Alexander S Pristupa; Tadeusz Robak; Jeff P Sharman; David Simpson; Lukáš Smolej; Eugen Tausch; Adeboye H Adewoye; Lyndah K Dreiling; Yeonhee Kim; Stephan Stilgenbauer; Peter Hillmen
Journal:  Lancet Oncol       Date:  2017-01-28       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.